Prenatal androgen treatment alters body composition and glucose homeostasis in male rats

Milos Lazic, Fraser Aird, Jon E Levine1 and Andrea Dunaif

Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University, Chicago, Illinois 60611, USA
1Department of Neurobiology and Physiology, Northwestern University, Evanston, Illinois 60208, USA

(Correspondence should be addressed to A Dunaif; Email: a-dunaif@northwestern.edu)

Abstract

Prenatal androgen produces many reproductive and metabolic features of polycystic ovary syndrome in female rodents, sheep, and monkeys. We investigated the impact of such prenatal treatment in adult male rats. Pregnant dams received free testosterone (T; aromatizable androgen), dihydrotestosterone (D; nonaromatizable androgen), or vehicle control (C) on embryonic days 16–19. Neither of the prenatal androgen treatments resulted in increased body weight from weaning to age 65 days in males. However, at 65 days, there were significant increases in retroperitoneal (P<0.01 T versus C; P<0.05 D versus C), epididymal (P<0.05 T versus C), and subcutaneous (P<0.01 T versus C) fat pads in prenatally androgenized males. While both androgens altered body composition, subcutaneous fat depots increased only in T males. T males had elevated glucose levels (P<0.01) compared to C males. There were no differences among the three groups in insulin sensitivity, circulating lipid and leptin levels, or hepatic triglyceride content. Real-time PCR analysis of insulin signaling pathway genes in retroperitoneal fat revealed a transcriptional downregulation of adipin and insulin receptor substrate-1 in T and α-1D adrenergic receptor in D compared to C males. We conclude that transient exposure to androgen excess in utero increases body fat in adult male rats. Only T males exhibit increased circulating glucose levels and subcutaneous fat suggesting that these changes may be mediated by aromatization of androgen to estrogen rather than by direct androgenic actions.

Journal of Endocrinology (2011) 208, 293–300

Introduction

Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects 5–10% of premenopausal women (Ehrmann 2005). Hyperandrogenemia is the cardinal reproductive feature of this syndrome (Legro et al. 1998), whereas insulin resistance is central to the metabolic phenotype (Dunaif 1997). Familial aggregation of PCOS is well documented, suggesting a genetic susceptibility to this disorder (Legro et al. 1998, Urbanek 2007). First-degree female relatives of women with PCOS have an increased prevalence of hyperandrogenemia, insulin resistance, and metabolic syndrome (Sam et al. 2005, 2006). Brothers of women with PCOS have elevated levels of dehydroepiandrosterone sulfate (Legro et al. 2002) and metabolic abnormalities including insulin resistance and dyslipidemia (Yildiz et al. 2003, Yilmaz et al. 2005, Sam et al. 2008). These findings are consistent with the hypothesis that some metabolic and reproductive abnormalities in PCOS are heritable and are not sex specific.

Prenatally androgenized (PA) female nonhuman primates and sheep, two animal models for PCOS, show most of the reproductive and metabolic defects seen in women with PCOS. Furthermore, we have shown deeminification of the GnRH neurosecretory system (Foecking & Levine 2005) and increased adiposity, circulating insulin and lipid levels, as well as hepatic triglyceride (TG) content in adult PA female rats (Demissie et al. 2008). These findings suggest that fetal exposure to androgen excess in female rodents programs for both reproductive and metabolic features of PCOS. However, there have been limited investigations of the phenotype of the male offspring in these PCOS animal models. Bruns et al. (2004) showed that adult PA male rhesus monkeys also exhibit insulin resistance and impaired insulin secretion, similar to PA female monkeys. PA male sheep developed oligospermia and reduced sperm motility (Recabarren et al. 2008), while PA male rats showed a decrease in anogenital distance (Wolf et al. 2002). The aim of this study is to determine whether intrauterine androgen excess programs for the metabolic features of PCOS in adult male rats, as has been previously seen in PA female rats. We also seek to determine whether the resulting metabolic phenotype is mediated by the androgenic or estrogenic pathway. These experiments assess the potential link between fetal exposure to androgen excess in males and metabolic features similar to those observed in first-degree male relatives of women with PCOS.
Materials and Methods

Animal treatments and diet

All rodent procedures were approved by the Animal Care and Use Committee at Northwestern University (Evanston, IL, USA). Rats were housed at 23–24 °C on a 14 h light:10 h darkness cycle.

Time-pregnant female Sprague–Dawley rats were obtained from Charles River (Portage, WI, USA) at day 14 of gestation and treated from embryonic day 16 (E16) to E19 with daily s.c. injections of either 5 mg of an aromatizable androgen testosterone (T, n = 6; T-1500, Sigma), 5 mg of a non-aromatizable androgen 5α-dihydrotestosterone (D, n = 7; Sigma) both dissolved in 500 μl sesame oil (S3547, Sigma)/benzyl benzoate (B6630, Sigma) or the vehicle as a control (C, n = 8). This treatment paradigm was designed to mimic in female fetuses the fetal T surge that is observed in male rats (Foecking & Levine 2005). The male fetuses were, therefore, exposed to supraphysiologic androgen levels. The D dose was selected based on our previous finding that 5 mg D produced a similar degree of masculinization of the anogenital distance as 5 mg T in PA female rats (Foecking et al. 2005). In preliminary experiments, we found no significant differences in either female to male offspring ratio, number of pups per litter, or birth weights between T, D, or C animals (unpublished observations). All litters were weaned and males were separated from females at 21 days of age and housed 2–3 per cage, unless otherwise stated. Once weaned, rats were fed regular rat chow diet (3.30 kcal/g with 24% as protein, 4% as fat by weight; Harlan–Teklad, Madison, WI, USA) and water made available ad libitum. Body weight (BW) was monitored weekly from 14 to 63 days. Food intake was monitored twice a week starting at 21 days (weaning) to 12 weeks in cages with individually housed male rats and their BW was recorded up to 22 weeks.

Study protocols

At weaning, males were either placed 2–3 per cage (29 C, 27 T, 32 D) or individually housed to precisely monitor changes in BW and food intake (8 C, 8 T, 10 D; Fig. 1). Group-housed adult male rats at 65–70 days of age (16 C, 15 T, 16 D) were fasted overnight, anesthetized with CO2, weighed, and decapitated. In order to examine insulin signaling, roughly half of the animals in all experimental groups were injected i.p. with 5 U of regular human insulin (NovoNordisk, Princeton, NJ, USA) in 100 μl of 0.9% sodium chloride (Abraxis, Schaumberg, IL, USA), and half were injected with 100 μl of 0.9% sodium chloride, 10 min before killing. Liver, adipose tissue depots (retroperitoneal, epididymal, and subcutaneous), and soleus muscles were excised, weighed, frozen, and stored at −80 °C for further analyses. Tissues from both saline- and insulin-treated rats were used for analyses of body composition and hepatic TG content (16 C, 15 T, 16 D), since the acute administration of insulin would not alter these end points.

Dynamic studies

Dynamic studies of glucose homeostasis were performed in group-housed adult male rats at 60–65 days of age (16 C, 13 T, 18 D) with jugular catheters implanted 1 day before testing (Fig. 1). Intraperitoneal glucose tolerance test (IPGTT) was performed after an overnight fast (~15 h). A baseline blood sample was followed by i.p. injection of 1 g/kg BW dextrose and blood sampling at 2, 5, 10, 15, 30, 60, 90, and 120 min. The baseline blood sample was used to determine the fasting glucose, insulin, C-peptide, leptin, and total cholesterol and TG levels. Intraperitoneal insulin tolerance test (IPITT) was performed after 4 h of fasting. A baseline blood sample was obtained followed by i.p. injection of 1 U/kg BW insulin and blood sampling at 15, 30, 60, 90, and 120 min. Animals were allowed a minimum of 48 h to recuperate between the IPGTT and IPITT.

Figure 1 Study schema with the number of animals used in each experiment. IPITT, intraperitoneal insulin tolerance test; IPGTT, intraperitoneal glucose tolerance test; SAL, saline baseline; INS, insulin stimulated; MRI, magnetic resonance imaging.
Hormone assays, plasma lipids, and hepatic TG content

Whole blood glucose levels were measured using Prestige Smart System Glucose Monitor (Home Diagnostics, Inc., Fort Lauderdale, FL, USA). Insulin and leptin levels were measured by Ultra Sensitive Rat Insulin and Rat Leptin ELISA kits respectively (Crystal Chem, Inc., Downers Grove, IL, USA). C-peptide was measured by Rat C-Peptide I and II ELISA kit (ALPCO Diagnostics, Salem, NH, USA). Circulating TG and cholesterol levels and hepatic TG content were assessed by spectrophotometric assay (Infinity TG and Cholesterol Reagent kits, Thermo Fisher Scientific, Pittsburgh, PA, USA). Circulating free fatty acids (FFA) were measured by the Wako HR series NEFA-HR (2), an in vitro enzymatic colorimetric method assay for the quantitative determination of FFA in serum (Wako Diagnostics, Richmond, VA, USA). Hepatic TG content was expressed as percent of protein content as described previously (Sundaram et al. 2005).

Gene expression profiling

Total RNA was extracted and purified from 100 mg of retroperitoneal fat (n=8 per group of saline-treated animals) using the RNeasy Lipid Tissue Mini kit (Qiagen). This fat pad was chosen since it was increased in both T and D as compared to C rats and it is also a major visceral fat depot implicated in development of insulin resistance (Gabriely et al. 2002). In all, 1 μg of retroperitoneal fat RNA from each rat was reverse transcribed and quantitative real-time PCR (qPCR) analysis of 84 insulin-signaling-pathway-related genes was performed using rat-specific Insulin Signaling RT2 Profiler PCR Arrays (SABiosciences, Frederick, MD, USA) according to the manufacturer’s protocol. The complete list of the genes analyzed is available online at http://www.sabiosciences.com/rt_pcr_product/HTML/PARN-030A.html. Relative gene expression levels were normalized to the average of five housekeeping genes: large ribosomal protein P1, hypoxanthine phosphoribosyltransferase 1, ribosomal protein L13A, lactate dehydrogenase A, and β-actin. Data analysis was performed using ΔΔCt-based fold-change method (Livak & Schmittgen 2001).

Western blotting

Liver, soleus muscle, and retroperitoneal fat lysates were resolved using SDS-PAGE on 7.5% gels and immunoblotted with specific antibodies to AKT and phospho-AKT (ser473) (Cell Signaling, Beverly, MA, USA), and appropriate secondary antibody (goat anti-rabbit HRP conjugates; Cell Signaling). Retroperitoneal fat lysates (n=8 per group of saline-treated animals) were resolved using SDS-PAGE on

Figure 2  Body weight and body composition. (A) There were no significant differences in BW among control (C; open squares), testosterone (T; black triangles) and dihydrotestosterone (D; black circles) males. (B) Body composition: T males (striped bars) had significantly increased retroperitoneal, epididymal and subcutaneous fat pad weights compared to C males (open bars). D males (black bars) had significantly increased retroperitoneal fat pad weight compared to C males. Values are mean ± S.E.M. C, n=16; T, n=15; D, n=16. *P<0.05, **P<0.01, ***P<0.001 versus C. †P<0.05 T versus D. (C) Representative MRI axial images of visceral area (renal section) in C, T, and D males showed a modest increase in retroperitoneal fat content in D compared to C males and a more striking increase in both mesenteric and retroperitoneal fat depots in T compared to C males; (1) retroperitoneal, (2) mesenteric, and (3) subcutaneous fat.
4–20% gradient gels and immunoblotted with specific antibodies to adipin L-21 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), insulin receptor substrate-1 (IRS-1; Millipore Corporation, Billerica, MA, USA) and pan-actin (Cell Signaling), and appropriate secondary antibodies (goat anti-rabbit HRP conjugates for IRS-1 and pan-actin, and rabbit anti-goat HRP conjugates for adipin; Cell Signaling and Santa Cruz Biotechnology respectively). We did not perform western blot analysis for the α-1D adrenergic receptor (ADRA1D) due to the lack of specificity of commercially available antibodies (Jensen et al. 2009). Both treatment groups and vehicle controls were run together on the same gels. Bands were visualized and analyzed as described previously (Corbould et al. 2006), with minor modifications. Immunoblots were quantified using a high-resolution scanner and the density was calculated by ImageJ software (National Institutes of Health, Bethesda, MD, USA). Phosphorylation was expressed as the ratio of phosphorylated to total protein.

**Fat distribution by magnetic resonance imaging (MRI)**

A 3T whole body MR scanner and an eight-channel knee coil were used to obtain high-resolution images of the whole body of the rat. Four animals per group (Fig. 1) were scanned at 75 days of age immediately after killing. The knee coil allowed the entire body of the rat to be imaged without having to move the animal but still afforded high signal to noise ratio. The imaging included a standard spin echo anatomic scan, a water suppressed image, and a fat suppressed image. The latter two images were used to mask the standard imaging to automate the analysis. The standard spin echo imaging parameters were repetition time $T_z =$ 500 ms, echo time $T_e =$ 11 ms, field of view $=75$ mm, matrix = 256, slice thickness of 2 mm. The inplane resolution was 0.29 mm. With two averages the total acquisition time was 3.2 min. This technique allowed us to gain axial images of visceral area and thus support our fat pad dissection data.

**Statistical analysis**

Repeated measures two-way ANOVA with time and treatment as factors was applied to BW and IPITT with a Bonferroni’s post hoc test to determine which groups differed significantly. The area-under-the curve for insulin and glucose levels during the IPGTT was determined according to the trapezoidal rule. For all other analyses, one-way ANOVA with Tukey’s or the Kruskal–Wallis with Dunn’s post hoc test was used according to normality of the data. Data are reported as mean ± S.E.M. with significance at $P < 0.05$. All analyses were performed using GraphPad Software (GraphPad Software, Inc., San Diego, CA, USA).

**Figure 3** Biochemical changes. (A) Serum glucose levels were significantly increased in T (striped bars) compared to C males (open bars), **$P < 0.01$ versus C. (B) Serum insulin levels and (C) insulin to C-peptide molar ratio were not significantly different among C, T, and D males (black bars). Values are mean ± S.E.M. C, $n = 17$; T, $n = 14$; D, $n = 19$.

**Figure 4** Dynamic testing. There were no significant differences in (A) glucose and (B) insulin levels during IPGTT; (C) percent basal glucose during IPITT among C (open squares), T (black triangles), and D males (black circles). Values are mean ± S.E.M. C, $n = 16$; T, $n = 13$; D, $n = 18$. 

Journal of Endocrinology (2011) 208, 293–300
Results

Baseline features

There were no differences in BW days 14–63 among prenatal T, D, and C group-housed males (Fig. 2A). There were also no differences among T, D, and C males in food intake (up to 12 weeks) or BW (up to 22 weeks) of age in individually housed males (data not shown). However, at 65–70 days, the retroperitoneal fat depots were increased by almost 60% in T compared to C males (P < 0.001) and 30% in D compared to C males (P < 0.05; Fig. 2B). Both epididymal (P < 0.05) and subcutaneous fat (P < 0.01) were increased (20–30%) in T compared to C males. Subcutaneous fat depots were increased only in T males (P < 0.05, T versus D; Fig. 2B). Representative axial MRI images of the visceral area (renal section) show a modest increase in retroperitoneal fat content in D compared to C males and a more striking increase in both mesenteric and retroperitoneal fat depots in T compared to C males (Fig. 2C).

T males had elevated fasting glucose levels (P < 0.01) compared to C males, but there was no significant difference in circulating insulin levels among the T, D, and C males (Fig. 3). There were no significant differences in the insulin to C-peptide molar ratio (Fig. 3) or in circulating C-peptide or leptin levels (not shown). There were also no differences in TG, cholesterol, or FFA levels or in hepatic TG content (not shown).

Dynamic testing

Following IPGTT, there were no differences in glucose or insulin responses among T, D, and C males (Fig. 4). There were no differences in insulin sensitivity assessed by IPITT among T, D, and C males (Fig. 4).

Insulin signaling

There were no significant differences in insulin-stimulated activation of AKT (phospho-AKT to AKT ratio) in the soleus muscle, liver, or retroperitoneal fat pads among T, D, and C males (Fig. 5). Analysis of insulin signaling pathway genes in retroperitoneal fat by qPCR revealed a significant downregulation of adipin/complement factor D (Adn/Cfd) and Irs-1 mRNA levels in T males, and Adra1d mRNA levels in D compared to C males (Table 1). A trend was observed in IRS-1 protein abundance in retroperitoneal fat, expressed as percent standard and normalized to pan-actin levels: 122 ± 12 in C, 67 ± 18 in T, and 87 ± 17 in D males (mean ± S.E.M., one-way ANOVA, P = 0.12, not shown). There were no significant differences detected in total protein abundance of adipin normalized to pan-actin levels in retroperitoneal fat pads among T, D, and C males (not shown).

Discussion

We have previously reported that prenatal androgen excess programs for features of the metabolic syndrome in adult female rats (Demissie et al. 2008). This study reveals that prenatal androgen excess programs male rat offspring for increased body fat mass and fasting glucose levels in early adulthood, although there were no changes in total BW. In particular, at 65 days of age, prenatal T treatment significantly increased both visceral (retroperitoneal and epididymal) and subcutaneous fat depots, while prenatal D treatment increased

![Figure 5](https://www.endocrinology-journals.org/)

Figure 5 Insulin signaling (represented as a phospho-AKT:AKT ratio) after 10 min i.p. insulin (5 U). No differences in insulin action were detected in (A) the skeletal muscle, (B) the liver, and (C) retroperitoneal fat among C (open bars), T (striped bars), and D males (black bars). Tissue-specific representative western blot images of phospho-AKT are shown above the figures. Values are mean ± S.E.M. C, n = 8 saline; T, n = 5 insulin; D, n = 6 insulin. 
only retroperitoneal fat depots compared to C males. Circulating glucose levels were significantly increased and Ins-1 mRNA expression was significantly decreased in retroperitoneal fat in T males. Nevertheless, in both T and D males, there were no defects in glucose tolerance, insulin sensitivity, or insulin-mediated activation of AKT in the soleus muscle, liver, or retroperitoneal fat. Furthermore, there were no changes in circulating lipid, FFA, or leptin levels or in hepatic TG content with either PA treatment. These findings are in contrast to those in PA male nonhuman primates that exhibit both insulin resistance and impaired insulin secretion, while maintaining normal fasting serum glucose (Bruns et al. 2004).

Despite significantly increased fat mass, PA male rat total BW did not change, analogous to findings in PA male monkeys (Bruns et al. 2004). These findings suggest that PA alters body composition but not BW in male rats. In contrast, total BW as well as visceral and subcutaneous fat mass increased in PA females (Demissie et al. 2008). In addition, PA females developed increased serum insulin, TG, and cholesterol levels and hepatic TG content (Demissie et al. 2008), whereas T males developed increased fasting glucose levels. Furthermore, despite the marked increase in adipose tissue in PA males, there were no changes in leptin or FFA levels. We failed to detect significant decreases in insulin sensitivity or signaling in PA rats of both sexes. The maintenance of normal circulating glucose levels, despite increased circulating insulin levels, suggested the presence of insulin resistance in PA females (Demissie et al. 2008).

To gain further insight into the mechanism of the programming actions of prenatal androgens in males, we compared the effects of prenatal D to those of prenatal T. T can be converted to estrogen by the action of the aromatase enzyme, which, in humans, is expressed in many tissues, including the gonads, central nervous system, bone, placenta, and fetal liver (Mendelson & Kamat 2007). However, in most vertebrates, including rodents, the primary source of aromatase is the ovary (Mendelson & Kamat 2007). Therefore, in T-treated animals, reprogramming of fetal tissues could result from exposure to excess estrogen via the dam’s gonadal or fetal aromatization of androgens. Thus, the effect of prenatal T could be due to androgenic and estrogenic pathways. In contrast, D is a nonaromatizable androgen, which has conventionally been thought to signal only through androgenic pathways (McGuire et al. 1960). More recently, it has been shown that a metabolite of D, 5α-androstane-3β,17β-diol, may activate the estrogen receptors in rat prostate (Weihtua et al. 2001) and hypothalamus (Pak et al. 2005). However, other studies do not confirm the findings in the hypothalamus (Lindsey et al. 1998). Furthermore, the amount of 5α-androstane-3β,17β-diol produced in vivo is small and its circulating half-life is very short (Grover & Odell 1975). Therefore, it remains likely that the changes observed with prenatal D treatment reflect primarily androgenic actions.

The body composition data and MRI axial images of the visceral area suggest that T males had increased fat mass compared to both C and D males. In particular, subcutaneous fat was significantly higher in T males when compared to both C and D males. It is well documented that females, both humans and rodents, have a greater amount of subcutaneous fat distributed in the gluteal/femoral region, while males have a more central accumulation of fat (Björntorp 1991, Lonnqvist et al. 1997, Clegg et al. 2006). Vague (1956) was first to observe that the pattern of fat deposition in obese individuals might be influenced by relative amounts of androgenic and estrogenic sex hormones. Accordingly, it has been shown that estrogen excess in male rats produces a female-like fat distribution phenotype with increased subcutaneous compared to visceral fat deposition (Clegg et al. 2006). The finding of increased subcutaneous fat depots in T males suggests that a portion of prenatal T was aromatized to estrogen and programmed a more female-like body fat distribution. Conversely, prenatal D programmed for increased retroperitoneal fat without changes in subcutaneous fat. This finding is consistent with the observation that androgen receptor density is about two times lower in subcutaneous as compared to visceral fat adipocytes (Dieuonné et al. 1998), which would decrease the effects of androgens on subcutaneous adipose tissue.

In order to further delineate the mechanisms leading to the differences in body composition in PA males, we performed expression profiling of insulin signaling pathway genes in retroperitoneal fat. This fat depot was chosen since it was increased in both T and D males. It is also a major visceral fat pad implicated in development of insulin resistance (Barzilai et al. 1998, Gabriely et al. 2002). We found significant downregulation of Adn and Ins-1 mRNA levels in T and Adra1d mRNA levels in D males. Adn, also known as complement factor D, is a serine protease, which stimulates

---

**Table 1** Expression profiling of insulin-signaling-pathway-related genes in retroperitoneal fat of male rats. Values are means ± S.E.M.

<table>
<thead>
<tr>
<th>Group</th>
<th>C</th>
<th>T</th>
<th>D</th>
<th>One-way ANOVA (P value)</th>
<th>Gene description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adn/Cfd</td>
<td>100.0±8.6</td>
<td>62.5±7.3**</td>
<td>87.3±8.3</td>
<td>0.01</td>
<td>Adipin/complement factor D (target gene for PPARγ)</td>
</tr>
<tr>
<td>Adra1d</td>
<td>100.0±14.3</td>
<td>77.9±13.6</td>
<td>59.7±11.0*</td>
<td>0.04</td>
<td>Adrenergic, α1D, receptor (PI3K pathway)</td>
</tr>
<tr>
<td>Irs-1</td>
<td>100.0±12.9</td>
<td>52.8±7.8*</td>
<td>69.7±12.3</td>
<td>0.03</td>
<td>Insulin receptor substrate-1 (insulin receptor-associated protein)</td>
</tr>
</tbody>
</table>

n=7–8/group, expressed as percent fold-change from controls. *P<0.05, **P<0.01 versus C.
glucose transport for TG accumulation in fat cells, inhibits lipolysis, and is involved in the alternative complement pathway (Ronzi et al. 2006). Interestingly, another complement factor – C3, closely related to Adhr and associated with insulin resistance, is downregulated by neonatal estrogen excess in rats (Alexanderson et al. 2009).

Sex steroids play an important and complex role in preadipocyte differentiation and proliferation. Moreover, IRS-1 has been shown to have a pivotal role in adipocyte differentiation through the activation of proliferator-activated receptor γ (Miki et al. 2009). These observations raise the possibility that the elevation in prenatal androgens caused an alteration in IRS-1 expression, which, in turn, programmed for increased adiposity in adulthood. However, Dieudonne et al. (2000) showed that T reduced the differentiation of preadipocytes extracted from the epididymal tissue of male rats in a dose-dependent manner, suggesting that androgens have a primarily antiadipogenic role on visceral fat depots in the adult. This observation is in contrast to the in vivo effects of androgens on preadipocytes and adipose tissue development. Castrated male rats display a significant decrease in visceral fat depots (Clegg et al. 2006), while PA first-calf heifers had greater fat deposition and increased overall growth rates (Reiling et al. 1997). In agreement with our studies, these observations suggest that androgens exhibit proadipogenic effects in vivo at both pre- and postnatal stages. It is also possible that reduced expression of Adra1d in D males decreased the rates of lipolysis (Lafontan & Berlan 1993), resulting in increased deposition of fat (Jocken & Blaak 2008). Contrary to our expectations, there were no changes in the expression levels of genes directly involved in fatty acid metabolism or in lipid/glucose transport, such as acetyl-CoA carboxylase, fatty acid synthase, glucose transporter type 4, or low-density lipoprotein receptor.

In concordance with the qPCR data, IRS-1 protein in retroperitoneal fat showed a trend for lower levels in T males as compared to C males. However, changes in neither IRS-1 nor adipin protein abundance reached statistical significance. This finding may reflect the fact that the limited number of available samples did not provide adequate statistical power. Furthermore, a lack of correlation between mRNA expression and protein abundance is frequently observed in complex biological systems, often due to the differences in translational efficiency, posttranscriptional regulation of gene expression, and protein stability (Maier et al. 2009). Nevertheless, even in the absence of detectable changes in protein abundance, the observed changes in mRNA levels suggest that prenatal androgens may program for altered transcriptional regulation of these genes. We did not perform western blot analysis for ADRA1D due to the lack of specificity of commercially available antibodies (Jensen et al. 2009).

We conclude that transient exposure to androgen excess in utero increases body fat levels in adult male rats. Only T males exhibit increased circulating glucose and subcutaneous fat, suggesting that these changes may be mediated by aromatization of androgen to estrogen rather than by direct androgenic actions. In contrast to PA female rats, PA males do not develop insulin resistance or dyslipidemia. These differences suggest that prenatal programming of some metabolic traits by androgens is sex specific.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the NIH grant P50 HD044405.

Acknowledgements

We thank Jorie Aardema, Brigitte Mann, and Jennifer Taylor for technical assistance.

References


Corbould A, Zhao H, Mizuno S, Aird F & Dunia A 2006 Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome. Diabetes 55 751–759. (doi:10.2373/diabetes.55.03.06.db05-0453)


Dunia A 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews 18 774–800. (doi:10.1210/er.18.6.774)


Linsey J, Wetzel WC, Couse JF, Stoker T, Cooper R & Korach KS 1998 Effects of castration and chronic steroid treatments on hypothalamic gonadotropin-releasing hormone content and pituitary gonadotropins in male wild-type and estrogen receptor-α knockout mice. *Endocrinology* 139 4092–4101. (doi:10.1210/endo.139.10.4092)


Urbanek M 2007 The genetics of the polycystic ovary syndrome. *Nature Clinical Practice. Endocrinology and Metabolism* 3 103–111. (doi:10.1038/ncpendm0400)


Received in final form 16 November 2010

Accepted 20 December 2010

Made available online as an Accepted Preprint

20 December 2010